Objective: Breast cancer patients frequently complain of cognitive dysfunction during chemotherapy. Patients also report experiencing a cluster of sleep problems, fatigue, and depressive symptoms during chemotherapy. We aimed to understand the complex dynamic interrelationships of depression, fatigue, and sleep to ultimately elucidate their role in cognitive performance and quality of life amongst breast cancer survivors undergoing chemotherapy treatment.
breast cancer, all symptoms within the symptom cluster, ie, fatigue, sleep complaints, and depressive symptoms, whether or not present before chemotherapy, worsen during cancer treatment. 4, 15 Chemotherapy-related cognitive problems are frequently reported by cancer survivors. [16] [17] [18] In a recent meta-analysis, 15 (12 in breast cancer) of 17 studies observed objective cognitive decline in patients treated with chemotherapy. 19 These problems can last for a few weeks, months, or even years after completion of chemotherapy. 20 Imaging studies have found alterations in cerebral activity in cancer patients before and after chemotherapy. 21 It is likely that the cognitive impairment seen in cancer patients might, at least in part, be related to fatigue, sleep problems, and depression. 22 Unraveling interrelationships between these symptoms and their impact on cognition poses computational challenges. Dimension reduction methods such as principal component analysis or clustering techniques are useful for deriving summary statements regarding association between the symptom cluster as a whole and cognitive symptoms in cancer patients. However, these methods use weighted combinations of suitably normalized symptom cluster variables, rendering results difficult to interpret for individual symptoms. While standard regression modeling cannot disentangle these complex associations, moderated regression methods could be used in this context. 23 , 24 Yet, alternative novel methods are needed to assess robustness of findings.
Bayesian graphical networks are a powerful approach for examining multivariate relationships. Bayesian networks provide algorithms for discovering and analyzing structure with intuitive graphs for visualizing interrelationships amongst sets of variables. The initial development of Bayesian networks arose in computer science and artificial intelligence, 25 and since then it has become widely used in genomics, and medical applications. 26, 27 Bayesian networks have not been widely used in cancer symptoms research. Herein, we illustrate how to apply Bayesian networks to examine associations amongst symptoms related to chemotherapy treatment, and their role in cognitive dysfunction, and quality of life.
Our goal is to demonstrate how this powerful computational method can be used to explore complex interrelationships between variables, and possibly guide design of intervention studies. Fitting a Bayesian network requires learning its structure (ie, which nodes in the graph are connected) and parameters (ie, estimation of conditional probabilities). Specifically, let X comprise the set of variables X i (eg, X 1 = fatigue, X 2 = sleep quality, X 3 = mood, X 4 = cognition)
| BRIEF DESCRIPTION OF BAYES NETWORK METHODOLOGY
and M be a Bayesian network on X, ie, a graph of edges between variables in X, as in Figure 1 . The model M encodes conditional independencies that imply a factoring of the joint probability distribution p(X) of X:
where pa(X i ) denotes variables ("parents") in X with directed edges (ie, arrows) leading to X i . To learn the structure of the graph M (eg, links, or edges, between fatigue, sleep, mood, and cognition in our application), efficient constraint-based, search-score, and hybrid algorithms can be implemented. 28 For a given graph M, parameters ß of p(X) can be estimated by regression methods, using multivariate Gaussian (after appropriate transformation if needed) or nonparametric distributions for continuous, and multinomial distributions for categorical variables. 
| Study sample and measures
We conducted a secondary analysis of an existing database of a completed NIH-funded study (2004) (2005) (2006) (2007) (2008) (2009) (2010) on the relationship between sleep, fatigue, mood, and cognition in breast cancer patients (PI Ancoli-Israel). Details on the study design and protocol have been previously published. 9 The study was approved by the UCSD Human
Research Protections Committee (protocol #s 080120 and 120187) and the UCSD Moores Cancer Center's Protocol Review and Monitoring Committee. We briefly describe the study sample and measures pertinent to our study.
| Study sample
The study recruited 74 newly diagnosed stage I to III breast cancer patients (mean age = 51.8 years) who were scheduled to receive chemotherapy and followed them for 1 year. Data were collected at 3 time points: before the start of chemotherapy (baseline; BL), at the end of cycle 4 chemotherapy (C4), and 1 year after the start of chemotherapy (Y1). In order to reduce confounding by other medical conditions or medications, the study excluded pregnant women, patients with significant anemia, patients currently receiving radiotherapy or bone marrow transplants or treatment for sleep apnea or periodic limb movements in sleep. Also, patients with current diagnosis of major depression, anxiety or psychotic disorder, and patients using medications known to influence sleep for 3 months prior to enrollment, were excluded.
Participant characteristics are provided in Table 1 . Briefly, 88%
were white, and 51% were college graduates, and close to 70% had ; and the Letter and Category 38 (animals) Fluency test (total words generated).
A summary measure of cognitive ability, a NP composite score, was computed as follows: each component raw test score was converted to a z-score by subtracting the baseline mean and dividing by the standard deviation. Z-scores were coded so that higher scores represented better functioning, and the composite score was defined as the mean of z-scores over the entire battery. As supplementary material, mean (SD) of the individual test scores at each study time point is provided in Table S1 .
| Previous analyses of longitudinal symptoms and cognition
We have previously shown 9 
| STATISTICAL METHODS
We calculated summary statistics of demographic factors, as well as, mean (SD) at BL, C4, and Y1 for the symptom cluster (sleep quality, fatigue, mood), QoL, and cognition.
We fit a Bayesian network to examine multivariate relationships between the symptom cluster, quality of life and cognition, before, during, and after chemotherapy. We also included demographic variables We used a score-based hill-climbing algorithm to infer network structure and applied bootstrap resampling to learn a set of 500 network structures. We then averaged these networks in an effort to reduce the impact of locally optimal (but globally suboptimal) networks on learning and inference. The averaged network is a more robust model with better predictive performance than choosing a single, high-scoring network. 28 To quantify stability of inferred edges, we computed arc strength and direction strength. Arc strength was calculated as the frequency of an edge occurring between 2 variables across the 500 bootstrapped network structures; similarly, directional strength was assessed as the frequency of the observed direction reoccurring in the set of learned network structures. We inferred conditional independencies between variables via the theory of Markov blankets of networks. 28 We applied Bayesian information criteria (BIC) and posterior model probabilities to compare candidate networks. 39 Lower BIC scores indicate better fit; score differences >5
(respectively, between 2.2 and 5) between 2 models strongly (respectively moderately) favor the lower-scoring model; differences <2.2 indicate similar fit for both models. Models were fitted using the R package bnlearn. 28 
| RESULTS
Longitudinal scores (Table 2) indicate that, as noted previously, 9 symptoms and QoL worsened during chemotherapy (BL-C4) on average but were generally comparable to BL levels by Y1. Cognitive performance did not change significantly during chemotherapy but was significantly higher at year 1 compared with BL.
| Bayesian network results

| Decomposition of probability distribution
Using the derived network, we decomposed the joint probability distribution of all 20 variables (2 demographic, and 6 symptoms/outcomes at 3 time points) as a product of conditional distributions. Specifically, letting X represent the vector of all the variables, we have the following factorization. The suffix 0 is BL, 1 is C4, and 2 is Y1.
P(A|B) denotes the conditional distribution, ie, probability of a variable A, given that we know the value of variable B. Thus, the above decomposition converts the complex model comprising 20 variables BL-C4-Y1 model:
into simpler "local" components and highlights subsets of factors that directly influence each variable. In fact, in our network (Figure 1 ), the maximum number of parents, ie, directed edges pointing to any variable, is 3 (eg, Fatigue at Y1 has parents Fatigue and Sleep at C4, and QoL at Y1), thus substantially fewer than the maximum of 19 possible directed edges. Below, we highlight key findings and describe how to infer (in)dependencies between variables.
| Cognitive functioning and symptoms
The network elicits local structure, so that we can identify parents, namely variables that directly influence any given factor. For example, age was the parent of BL cognition, whereas BL cognition and C4 sleep quality were parents of C4 cognition. The bootstrapped arc strength for age on BL cognition was 0.86 indicating that age was reproducibly associated with cognition. The regression estimate (Table 3) was negative for age indicating that younger age was associated with better cognition at BL.
At C4, cognition was (directly) positively influenced by BL cognition (as might be expected) but negatively influenced by C4 sleep score, indicating that worse sleep quality at the end of chemotherapy was associated with worse cognition. Interestingly, via the Markov property, we infer that after accounting for cognition and C4 sleep, C4 cognitive function was independent of all other variables. We also note that although not directly linked, C4 fatigue affected C4 cognition through C4 sleep quality. Moreover, C4 depression indirectly affected cognition through a direct effect on C4 fatigue and corresponding downstream effects on C4 sleep quality.
At the 1-year follow-up, cognition was directly influenced by both BL cognition and C4 cognition, with, as expected, positive regression coefficients for both variables, indicating that higher BL and C4 cognition scores were associated with better Y1 cognition. Interestingly, no symptoms directly influenced Y1 cognition. Several symptoms showed direct cross-sectional and temporal links. At BL and C4, mood was the (only) parent of fatigue with strong cross-sectional links (arc strength ≥ 0.87); also, regression estimates (Table 3) were positive, indicating that higher CESD scores (ie, worse mood) were associated with higher fatigue scores (ie, worse fatigue).
| Symptom clusters, quality of life (QoL), and functional outcomes of sleepiness (FOS)
Further, although not exhibiting high consistency, C4 fatigue and sleep quality were parents of Y1 fatigue (arc-strengths ≤ 0.67); Y1 sleep was directly influenced by Y1 mood and BL sleep (arc-strengths ≤ 0.76).
Thus, these links suggest a temporal cluster of sleep, mood, and fatigue.
| Comparing networks
Given our focus on cognitive symptoms and quality of life during and after chemotherapy, we conducted sensitivity analyses to test the value of the learned subnetworks for Cognition and QoL. We created a new network in which all edges to-and from-Cognition were removed and refitted this network to the data. The BIC score for this new network was more than 164 points higher than that of the original networks, indicating far superior fit of the original fitted network and providing support for the identified links to cognition. Similarly, a network in which QoL was isolated (ie, all edges to-and from-QoL were deleted) had a 226 point higher BIC score, again strongly favoring the original fitted models.
We also tested the impact of removing a specific edge from the network as follows. If we removed the We then fit a second network in which we constrained the C4-Y1 subnetwork to be identical to the corresponding chemotherapy treatment phase sub-network (the learned BL-C4 sub-network). This constrained network had a BIC score of 4461.6, a 77-point higher score, indicating substantially worse fit for the constrained model compared with the original network.
| DISCUSSION
Most patients undergoing chemotherapy complain of symptoms such as fatigue, impaired sleep, and poor mood. Studies of these patients generally focus on average effects and note that mean scores for each of these symptoms usually worsen during chemotherapy. Not much is known regarding how these symptoms influence each other. In the current work, we aimed to address this gap. We applied a powerful
Bayesian network approach to discern inter-relationships amongst these symptoms and, furthermore, examined the role of these symptoms on QoL, functional outcomes of sleepiness, and cognitive functioning. Unraveling inter-relationships amongst these many factors is a complex computational problem, and Bayesian networks provide a first glimpse at how we might decompose this large multivariate distribution into a set of lower-dimensional relationships.
| Clinical implications
There are many potential clinical implications of this work. Understanding cross-sectional and longitudinal inter-relationships amongst symptoms, QoL and cognition could guide the design of effective interventions. For instance, our networks identified sleep quality as the primary symptom influencing cognition. Thus, an intervention aimed at improving sleep during chemotherapy could potentially mitigate some of the neurocognitive symptoms experienced by cancer patients.
We emphasize that our goal in the current analysis was not to assess whether cancer patients experienced cognitive dysfunction, a phenomenon that has been well studied, but rather to identify factors that might influence acute cognitive ability for a patient undergoing chemotherapy. Another finding of this work was that mood and fatigue directly influenced QoL and/or FOS in the chemotherapy period, and after accounting for the symptom cluster of sleep, mood, and fatigue, cognition was (conditionally) independent of QoL and FOS. Thus, an intervention aimed at improving this symptom cluster and implemented while patients are undergoing chemotherapy could have numerous benefits. 40 Using Bayes information criteria, we were able to confirm our hypothesis that inter-relationships between symptoms and outcomes would be different in the chemotherapy treatment phase (BL-C4) as compared with post-chemotherapy (C4-Y1). It is interesting to note similarities and differences between these networks. Post-chemotherapy quality of life and year 1 quality of life were each influenced by mood at the same time point, but post-chemotherapy quality of life was also influenced by concurrent fatigue which was not the case for year 1 quality of life, suggesting that interventions to improve mood during chemotherapy could improve post-chemotherapy quality of life. Similarly, while prior functional outcomes of sleepiness (FOS) score influenced subsequent level at all time points, post-chemotherapy FOS score was strongly influenced by concurrent fatigue, again suggesting that an intervention to reduce fatigue during chemotherapy could improve functional outcomes of sleepiness in breast cancer survivors.
Additional differences between the networks are evident in Figure 1 , but these differences were not reliable (arc strengths of these differing edges were <0.7).
| Strengths and limitations
The strengths of this work include a well-characterized cohort of patients undergoing chemotherapy, the use of bootstrap methods, and model averaging, which reduce overfit and improve replicability.
There are also limitations. Our sample size is modest and may have impeded our ability to discern important links. Also, our study did not collect self-reported pain, a factor that could have influenced the observed findings. Furthermore, Bayesian networks are inherently exploratory. Hence, these results need to be confirmed in other cohorts with larger sample sizes that include broad symptom inventories, including pain, and implement alternative computational strategies such as moderated regression. 23, 24 We used an established NP battery which affords the opportunity to evaluate objective cognitive performance during chemotherapy. However, self-reported cognitive deficits are commonly noted by cancer patients during treatment. It would be interesting to investigate if networks for self-reported versus objective cognition are similar, and we leave this question and other similar ones (eg, comparing objective sleep assessed via actigraphy to self-reported sleep) for a future study.
| CONCLUSIONS
In this article, we have introduced Bayesian networks, a machine learning methodology, to infer networks of symptom cluster and cognitive and psychosocial outcomes for breast cancer patients during and 1 year after undergoing chemotherapy. Our results identified separate pathways and potential links between symptoms, cognitive function and QoL. The network comparison analysis strongly favored the fitted networks, indicating that our findings are robust against alternative network structures. Our work illustrates that Bayesian networks could be a powerful tool in cancer symptoms research; we advocate their use in future studies.
